	US 12,295,963 B2
	Treating pain associated with diabetic peripheral neuropathy
Basil Rigas, Setauket, NY (US)
Assigned to MEDICON PHARMACEUTICALS, INC., Setauket, NY (US)
Filed by MEDICON PHARMACEUTICALS, INC., Setauket, NY (US)
Filed on Nov. 21, 2023, as Appl. No. 18/515,743.
Application 18/515,743 is a continuation of application No. PCT/US2022/072497, filed on May 23, 2022.
Claims priority of provisional application 63/192,248, filed on May 24, 2021.
Prior Publication US 2024/0100073 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/661 (2006.01); A61P 25/02 (2006.01); A61P 25/04 (2006.01)

CPC A61K 31/661 (2013.01) [A61P 25/02 (2018.01); A61P 25/04 (2018.01)]

29 Claims

1. A method of treating and/or preventing neuropathic pain associated with diabetic peripheral neuropathy (DPN) comprising administering a therapeutically effective amount of phosphosulindac (PS) to a subject in need thereof such that neuropathic pain associated with DPN is treated and/or prevented.